請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99963完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張永祺 | zh_TW |
| dc.contributor.advisor | Yung-Chi Chang | en |
| dc.contributor.author | 陳泓文 | zh_TW |
| dc.contributor.author | Hong-Wen Chen | en |
| dc.date.accessioned | 2025-09-22T16:09:43Z | - |
| dc.date.available | 2025-09-23 | - |
| dc.date.copyright | 2025-09-22 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-08-05 | - |
| dc.identifier.citation | 1. Li, D. and M. Wu, Pattern recognition receptors in health and diseases. Signal Transduct Target Ther, 2021. 6(1): p. 291.
2. Akira, S., S. Uematsu, and O. Takeuchi, Pathogen recognition and innate immunity. Cell, 2006. 124(4): p. 783-801. 3. Takeuchi, O. and S. Akira, Innate immunity to virus infection. Immunol Rev, 2009. 227(1): p. 75-86. 4. Bowie, A. and L.A. O'Neill, The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leukoc Biol, 2000. 67(4): p. 508-14. 5. Temperley, N.D., S. Berlin, I.R. Paton, D.K. Griffin, and D.W. Burt, Evolution of the chicken Toll-like receptor gene family: a story of gene gain and gene loss. BMC Genomics, 2008. 9: p. 62. 6. Jin, M.S., S.E. Kim, J.Y. Heo, M.E. Lee, H.M. Kim, et al., Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell, 2007. 130(6): p. 1071-82. 7. Kang, J.Y., X. Nan, M.S. Jin, S.J. Youn, Y.H. Ryu, et al., Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity, 2009. 31(6): p. 873-84. 8. Tobias, P.S., K. Soldau, J.A. Gegner, D. Mintz, and R.J. Ulevitch, Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem, 1995. 270(18): p. 10482-8. 9. Park, B.S., D.H. Song, H.M. Kim, B.S. Choi, H. Lee, et al., The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 2009. 458(7242): p. 1191-5. 10. Zanoni, I., R. Ostuni, L.R. Marek, S. Barresi, R. Barbalat, et al., CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell, 2011. 147(4): p. 868-80. 11. Hayashi, F., K.D. Smith, A. Ozinsky, T.R. Hawn, E.C. Yi, et al., The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature, 2001. 410(6832): p. 1099-103. 12. Yang, Q. and H.B. Shu, Deciphering the pathways to antiviral innate immunity and inflammation. Adv Immunol, 2020. 145: p. 1-36. 13. Chen, Y., J. Lin, Y. Zhao, X. Ma, and H. Yi, Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J Zhejiang Univ Sci B, 2021. 22(8): p. 609-632. 14. Alexopoulou, L., A.C. Holt, R. Medzhitov, and R.A. Flavell, Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 2001. 413(6857): p. 732-8. 15. Leonard, J.N., R. Ghirlando, J. Askins, J.K. Bell, D.H. Margulies, et al., The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci U S A, 2008. 105(1): p. 258-63. 16. Wang, Y., L. Liu, D.R. Davies, and D.M. Segal, Dimerization of Toll-like receptor 3 (TLR3) is required for ligand binding. J Biol Chem, 2010. 285(47): p. 36836-41. 17. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, et al., Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science, 2004. 303(5663): p. 1526-9. 18. Akira, S. and K. Takeda, Toll-like receptor signalling. Nat Rev Immunol, 2004. 4(7): p. 499-511. 19. Duan, T., Y. Du, C. Xing, H.Y. Wang, and R.F. Wang, Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Front Immunol, 2022. 13: p. 812774. 20. Sato, S., M. Sugiyama, M. Yamamoto, Y. Watanabe, T. Kawai, et al., Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol, 2003. 171(8): p. 4304-10. 21. Kawai, T., O. Takeuchi, T. Fujita, J. Inoue, P.F. Muhlradt, et al., Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol, 2001. 167(10): p. 5887-94. 22. Matsumoto, M., H. Oshiumi, and T. Seya, Antiviral responses induced by the TLR3 pathway. Rev Med Virol, 2011. 21(2): p. 67-77. 23. Rehwinkel, J. and M.U. Gack, RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol, 2020. 20(9): p. 537-551. 24. Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, et al., The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol, 2004. 5(7): p. 730-7. 25. Yoneyama, M., M. Kikuchi, K. Matsumoto, T. Imaizumi, M. Miyagishi, et al., Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol, 2005. 175(5): p. 2851-8. 26. Komuro, A. and C.M. Horvath, RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2. J Virol, 2006. 80(24): p. 12332-42. 27. Rothenfusser, S., N. Goutagny, G. DiPerna, M. Gong, B.G. Monks, et al., The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol, 2005. 175(8): p. 5260-8. 28. Kawai, T., K. Takahashi, S. Sato, C. Coban, H. Kumar, et al., IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol, 2005. 6(10): p. 981-8. 29. Smith, D.K. and H. Xue, Sequence profiles of immunoglobulin and immunoglobulin-like domains. J Mol Biol, 1997. 274(4): p. 530-45. 30. Taylor, V.C., C.D. Buckley, M. Douglas, A.J. Cody, D.L. Simmons, et al., The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem, 1999. 274(17): p. 11505-12. 31. Orr, S.J., N.M. Morgan, J. Elliott, J.F. Burrows, C.J. Scott, et al., CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood, 2007. 109(3): p. 1061-8. 32. Angata, T., Siglecs that Associate with DAP12. Adv Exp Med Biol, 2020. 1204: p. 215-230. 33. Crocker, P.R., J.C. Paulson, and A. Varki, Siglecs and their roles in the immune system. Nat Rev Immunol, 2007. 7(4): p. 255-66. 34. Angata, T., E.H. Margulies, E.D. Green, and A. Varki, Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc Natl Acad Sci U S A, 2004. 101(36): p. 13251-6. 35. Raich-Regue, D., P. Resa-Infante, M. Gallemi, F. Laguia, X. Muniz-Trabudua, et al., Role of Siglecs in viral infections: A double-edged sword interaction. Mol Aspects Med, 2023. 90: p. 101113. 36. Gonzalez-Gil, A., T.A. Li, J. Kim, and R.L. Schnaar, Human sialoglycan ligands for immune inhibitory Siglecs. Mol Aspects Med, 2023. 90: p. 101110. 37. Chen, G.Y., N.K. Brown, W. Wu, Z. Khedri, H. Yu, et al., Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1. Elife, 2014. 3: p. e04066. 38. Huang, P.J., P.Y. Low, I. Wang, S.D. Hsu, and T. Angata, Soluble Siglec-14 glycan-recognition protein is generated by alternative splicing and suppresses myeloid inflammatory responses. J Biol Chem, 2018. 293(51): p. 19645-19658. 39. Perez-Zsolt, D., J. Munoz-Basagoiti, J. Rodon, M. Elosua-Bayes, D. Raich-Regue, et al., SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. Cell Mol Immunol, 2021. 18(12): p. 2676-2678. 40. Lempp, F.A., L.B. Soriaga, M. Montiel-Ruiz, F. Benigni, J. Noack, et al., Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature, 2021. 598(7880): p. 342-347. 41. Jalloh, S., J. Olejnik, J. Berrigan, A. Nisa, E.L. Suder, et al., CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. PLoS Pathog, 2022. 18(10): p. e1010479. 42. Macauley, M.S., P.R. Crocker, and J.C. Paulson, Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol, 2014. 14(10): p. 653-66. 43. Lajaunias, F., J.M. Dayer, and C. Chizzolini, Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol, 2005. 35(1): p. 243-51. 44. Tsai, T.Y., M.T. Huang, P.S. Sung, C.Y. Peng, M.H. Tao, et al., SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection. J Clin Invest, 2021. 131(11). 45. Chen, W., C. Han, B. Xie, X. Hu, Q. Yu, et al., Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell, 2013. 152(3): p. 467-78. 46. Schmitt, H., S. Sell, J. Koch, M. Seefried, S. Sonnewald, et al., Siglec-H protects from virus-triggered severe systemic autoimmunity. J Exp Med, 2016. 213(8): p. 1627-44. 47. Zheng, Q., J. Hou, Y. Zhou, Y. Yang, B. Xie, et al., Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27. Cell Res, 2015. 25(10): p. 1121-36. 48. Kuroki, K., A. Furukawa, and K. Maenaka, Molecular recognition of paired receptors in the immune system. Front Microbiol, 2012. 3: p. 429. 49. Ali, S.R., J.J. Fong, A.F. Carlin, T.D. Busch, R. Linden, et al., Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. J Exp Med, 2014. 211(6): p. 1231-42. 50. Blixt, O., B.E. Collins, I.M. van den Nieuwenhof, P.R. Crocker, and J.C. Paulson, Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J Biol Chem, 2003. 278(33): p. 31007-19. 51. Yamanaka, M., Y. Kato, T. Angata, and H. Narimatsu, Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology, 2009. 19(8): p. 841-6. 52. Angata, T., T. Ishii, T. Motegi, R. Oka, R.E. Taylor, et al., Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol Life Sci, 2013. 70(17): p. 3199-210. 53. Schwarz, F., C.S. Landig, S. Siddiqui, I. Secundino, J. Olson, et al., Paired Siglec receptors generate opposite inflammatory responses to a human-specific pathogen. EMBO J, 2017. 36(6): p. 751-760. 54. Lin, S.Y., E.N. Schmidt, K. Takahashi-Yamashiro, and M.S. Macauley, Roles for Siglec-glycan interactions in regulating immune cells. Semin Immunol, 2025. 77: p. 101925. 55. Forsbach, A., J.G. Nemorin, C. Montino, C. Muller, U. Samulowitz, et al., Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol, 2008. 180(6): p. 3729-38. 56. Kurt, R.A., T. Newman, and C.W. Liew, Predicting the therapeutic efficacy of TLR stimulated macrophages for cancer treatment. Journal of Immunology, 2023. 210(1). 57. Cornish, A.L., S. Freeman, G. Forbes, J. Ni, M. Zhang, et al., Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Blood, 1998. 92(6): p. 2123-32. 58. Yin, H., H. Zhou, Y. Kang, X. Zhang, X. Duan, et al., Syk negatively regulates TLR4-mediated IFNbeta and IL-10 production and promotes inflammatory responses in dendritic cells. Biochim Biophys Acta, 2016. 1860(3): p. 588-98. 59. Stambolic, V. and J.R. Woodgett, Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J, 1994. 303 ( Pt 3)(Pt 3): p. 701-4. 60. Turnbull, I.R. and M. Colonna, Activating and inhibitory functions of DAP12. Nat Rev Immunol, 2007. 7(2): p. 155-61. 61. Bouchon, A., J. Dietrich, and M. Colonna, Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol, 2000. 164(10): p. 4991-5. 62. Bouchon, A., F. Facchetti, M.A. Weigand, and M. Colonna, TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature, 2001. 410(6832): p. 1103-7. 63. Hamerman, J.A., N.K. Tchao, C.A. Lowell, and L.L. Lanier, Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol, 2005. 6(6): p. 579-86. 64. Turnbull, I.R., S. Gilfillan, M. Cella, T. Aoshi, M. Miller, et al., Cutting edge: TREM-2 attenuates macrophage activation. J Immunol, 2006. 177(6): p. 3520-4. 65. Blasius, A., W. Vermi, A. Krug, F. Facchetti, M. Cella, et al., A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. Blood, 2004. 103(11): p. 4201-6. 66. Sjolin, H., S.H. Robbins, G. Bessou, A. Hidmark, E. Tomasello, et al., DAP12 signaling regulates plasmacytoid dendritic cell homeostasis and down-modulates their function during viral infection. J Immunol, 2006. 177(5): p. 2908-16. 67. Blasius, A.L., M. Cella, J. Maldonado, T. Takai, and M. Colonna, Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood, 2006. 107(6): p. 2474-6. 68. Mauad, T., L.A. Hajjar, G.D. Callegari, L.F. da Silva, D. Schout, et al., Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med, 2010. 181(1): p. 72-9. 69. Liu, S., Z. Huang, R. Fan, J. Jia, X. Deng, et al., Cycling and activated CD8(+) T lymphocytes and their association with disease severity in influenza patients. BMC Immunol, 2022. 23(1): p. 40. 70. Guo, K., D.J.K. Yombo, Z. Wang, Z. Navaeiseddighi, J. Xu, et al., The chemokine receptor CXCR3 promotes CD8(+) T cell-dependent lung pathology during influenza pathogenesis. Sci Adv, 2024. 10(1): p. eadj1120. 71. van de Sandt, C.E., M. Barcena, A.J. Koster, J. Kasper, C.J. Kirkpatrick, et al., Human CD8(+) T Cells Damage Noninfected Epithelial Cells during Influenza Virus Infection In Vitro. Am J Respir Cell Mol Biol, 2017. 57(5): p. 536-546. 72. Schmit, T., K. Guo, J.K. Tripathi, Z. Wang, B. McGregor, et al., Interferon-gamma promotes monocyte-mediated lung injury during influenza infection. Cell Rep, 2022. 38(9): p. 110456. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/99963 | - |
| dc.description.abstract | 在感染的過程中，類鐸受體能夠藉由識別病原相關分子模式以啟動先天性免疫反應。Siglec受體為廣泛表現在免疫細胞上的免疫調節分子，其能透過與病原體表面的唾液酸化配體結合，並和類鐸受體訊號路徑產生交互作用來調控免疫反應。Siglec-5與Siglec-14是主要表現在髓系細胞上的成對受體，儘管兩者具有高度相似的細胞外結構域，能夠辨識相同的配體，但它們卻會傳遞相反的胞內訊號：Siglec-5含有ITIM基序，可傳遞抑制型訊號；而Siglec-14則藉由含有ITAM基序的銜接蛋白DAP12傳遞活化型訊號。本研究利用嚴重病毒性肺炎的小鼠模型探討此成對受體在免疫調控中的功能。體外實驗結果顯示，在小鼠骨髓源性巨噬細胞(BMDM)中，表現Siglec-14可以促進類鐸受體活化或病毒感染後TNF的表現並抑制IL-10的生成。對於IFN-β，Siglec-14則呈現刺激特異性的調節作用：在Poly(I:C)或仙台病毒刺激時，Siglec-14能夠促進IFN-β表現，但在LPS-EK或H5N1感染後則呈現抑制效果。相較之下，Siglec-5傾向抑制IL-10與IFN-β的表現，對於TNF與IL-6的影響則相對有限。體內實驗中，儘管SIGLEC14Myeloid TG小鼠與野生型小鼠感染後的病毒量相似，但感染之後第三天SIGLEC14Myeloid TG小鼠嗜中性球與自然殺手細胞的數量明顯下降，而感染之後第六天SIGLEC14Myeloid TG小鼠CD8+ T細胞的比例與數量以及細胞因子IL-6與IFN-γ的含量均顯著上升。這些結果顯示，Siglec-14可能透過調控病毒感染期間免疫細胞的分布與活化狀態以促進肺部的發炎反應。總結而言，我們的研究結果表明Siglec-5與 Siglec-14在調節巨噬細胞反應及肺部免疫環境方面具有獨特且依賴刺激條件的功能。 | zh_TW |
| dc.description.abstract | Upon infection, Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns (PAMPs) and initiate immune responses. Siglecs, which are abundantly expressed on immune cells, serve as key immunomodulatory receptors that regulate immune activation by recognizing sialylated ligands on pathogens and interacting with TLR pathways. Among them, Siglec-5 and Siglec-14 are paired receptors primarily found on myelomonocytic cells. Despite having nearly identical extracellular domains, they transmit opposing signals: Siglec-5 inhibits signaling via an ITIM motif, whereas Siglec-14 activates immune responses through the ITAM-containing adaptor DAP12 upon engaging the same ligand. We investigated the functional roles of this receptor pair using mouse models of severe viral pneumonia. In vitro, Siglec-14 expression in mouse bone-marrow-derived macrophage (BMDMs) enhanced TNF and suppressed IL-10 after TLR stimulation or viral infection. Siglec-14 also regulated IFN-β in a stimulus-specific manner-enhancing expression following Poly(I:C) or Sendai virus stimulation, but suppressing it after LPS-EK or H5N1 exposure. In contrast, Siglec-5 consistently downregulated IL-10 and IFN-β with minimal impact on TNF or IL-6. In vivo, despite similar viral loads, SIGLEC14Myeloid TG mice displayed reduced neutrophils and NK cells on day 3 post-infection, but increased CD8⁺ T cells and elevated IL-6 and IFN-γ by day 6 compared to wild-type (WT) mice. These findings suggest Siglec-14 skews immune cell dynamics and promotes an inflammatory lung environment during viral infection. Together, our results demonstrate distinct and context-dependent roles for Siglec-5 and Siglec-14 in regulating macrophage responses and shaping pulmonary immunity. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-09-22T16:09:43Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-09-22T16:09:43Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 目次
口試委員會審定書 i 致謝 ii 中文摘要 iii Abstract iv 目次 vi 壹、 研究背景與動機 1 一、 模式識別受體(pattern recognition receptor) 1 1. 類鐸受體 1 2. Retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) 3 二、 唾液酸結合免疫球蛋白樣凝集素(Sialic acid-binding immunoglobulin-type lectins, Siglecs) 4 1. Siglec的基本介紹 4 2. Siglec與類鐸受體之間的交互作用 6 3. Siglec與病毒之間的交互作用 7 4. Siglec對於病毒感染後免疫反應之影響 7 5. 成對受體(paired receptor) 8 三、 研究動機 11 貳、 實驗材料與研究方法 12 一、 實驗材料 12 1. 細胞株 12 2. 病毒株 12 3. 引子 12 4. 酵素免疫分析套組 13 5. 抗體 14 6. 類鐸受體促效劑 16 7. 實驗用小鼠類別 16 二、 實驗方法 16 1. 製備L929 條件培養液 16 2. 培養小鼠骨髓源性巨噬細胞 16 3. 小鼠骨髓源性巨噬細胞活化方式 17 4. RNA萃取與即時連鎖聚合酶反應 18 5. 酵素免疫分析法 19 6. 西方墨點法 19 7. 培育表現人類SIGLEC基因之轉殖小鼠及基因型分型 20 8. 小鼠流感病毒感染與小鼠支氣管肺泡沖洗液收取 21 9. 病毒斑試驗 21 10. 小鼠肺組織勻漿 22 11. 小鼠肺組織切片、染色與組織病理情形判讀 22 12. 流式細胞儀分析支氣管肺泡沖洗液免疫細胞組成 23 13. mRNA穩定性測試 25 參、 研究結果 26 一、 Siglec-5與Siglec-14對於類鐸受體與病毒感染後免疫反應之調控 26 1. 基因轉殖小鼠Siglec-5、Siglec-14與模式識別受體之表現情形 26 2. Siglec-5與Siglec-14對於TLR1/2啟動後免疫反應之影響 27 3. Siglec-5與Siglec-14對於TLR4啟動後免疫反應之影響 28 4. Siglec-5與Siglec-14對於TLR3啟動後免疫反應之影響 29 5. Siglec-5與Siglec-14對於仙台病毒感染後免疫反應之影響 30 6. Siglec-5與Siglec-14對於H5N1感染後免疫反應之影響 31 7. Siglec-5與Siglec-14對於類鐸受體下游訊息傳遞路徑之影響 32 二、 流感病毒感染後SIGLEC14Myeloid TG小鼠免疫反應之分析 34 1. 流感病毒感染後小鼠病毒量之分析 34 2. 流感病毒感染後小鼠免疫細胞組成之分析 35 3. 流感病毒感染後小鼠細胞因子與趨化因子表現量之分析 36 4. 流感病毒感染後小鼠肺組織病理情形之分析 37 肆、 討論與未來研究方向 38 一、 BMDM與THP-1細胞結果相異之可能原因 38 二、 訊息傳遞路徑結果與mRNA及蛋白質表現量相異之可能原因 40 三、 流感病毒感染後SIGLEC14Myeloid TG小鼠死亡率較高之可能原因 42 參考文獻 44 研究圖表 50 附錄 86 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 類鐸受體 | zh_TW |
| dc.subject | Siglec | zh_TW |
| dc.subject | 流感病毒 | zh_TW |
| dc.subject | 第一型干擾素 | zh_TW |
| dc.subject | 抗發炎因子 | zh_TW |
| dc.subject | 促發炎因子 | zh_TW |
| dc.subject | Siglec | en |
| dc.subject | Influenza virus | en |
| dc.subject | Type I interferon | en |
| dc.subject | Pro-inflammatory cytokine | en |
| dc.subject | Toll-like receptors (TLRs) | en |
| dc.subject | Anti-inflammatory cytokine | en |
| dc.title | Siglec-5和Siglec-14對於模式識別受體與抗病毒免疫反應的調節作用 | zh_TW |
| dc.title | The role of Siglec-5 and Siglec-14 in regulating pattern recognition receptors and antiviral immunity | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 林志萱;顧家綺 | zh_TW |
| dc.contributor.oralexamcommittee | Jr-Shiuan Lin;Chia-Chi Ku | en |
| dc.subject.keyword | Siglec,類鐸受體,促發炎因子,抗發炎因子,第一型干擾素,流感病毒, | zh_TW |
| dc.subject.keyword | Siglec,Toll-like receptors (TLRs),Pro-inflammatory cytokine,Anti-inflammatory cytokine,Type I interferon,Influenza virus, | en |
| dc.relation.page | 88 | - |
| dc.identifier.doi | 10.6342/NTU202503855 | - |
| dc.rights.note | 未授權 | - |
| dc.date.accepted | 2025-08-05 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 微生物學研究所 | - |
| dc.date.embargo-lift | N/A | - |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf 未授權公開取用 | 5.57 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。